Press releases

 

 

Category

  • All
  • Financial
  • Corporate

Years

  • All
  • 2017
  • 2016
  • 2015

Cellnovo secures EUR 5m debt financing from Kreos Capital

10/05/2017 - Financial

Cellnovo reports that it has signed an initial structured debt financing agreement with Kreos Capital (Kreos), Europe's largest and leading provider of debt-financing solutions to high-growth companies.
Read more

Mise à disposition du rapport financier annuel 2016 (In French only)

27/04/2017 - Financial

Cellnovo annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des marchés financiers son rapport financier annuel au 31 décembre 2016.
Read more

Cellnovo Delivers First Commercial Batch of Insulin Cartridges with Manufacturing Partner, Flex

26/04/2017 - Corporate

Cellnovo announces that its manufacturing partner, Flex, has completed the first commercial batch of consumables for its diabetes management system.
Read more

Cellnovo announces its Full Year 2016 Results and Q1 2017 Sales

26/04/2017 - Financial

Cellnovo announces its full-year results for the financial year ended December 31, 2016, and its Q1 2017 sales.
Read more

Cellnovo announces that Diabeloop is launching a CE marking Registration Study on Artificial Pancreas with Cellnovo pump

20/04/2017 - Corporate

Diabeloop and Cellnovo Group announce today the launch of a CE marking cross-over registration study for the Artificial Pancreas solution developed by Diabeloop using the Cellnovo pump.
Read more

Cellnovo acquires commercial license for Artificial Pancreas Technology from TypeZero Technologies

18/04/2017 - Corporate

Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, and digital health company TypeZero Technologies, today announce the completion of a worldwide commercial license agreement for the integration and the commercialization of TypeZero’s Artificial Pancreas (AP) technology into Cellnovo’s mobile diabetes management systems.
Read more

Monthly information regarding the total number of voting rights and total number of shares of the Company

10/04/2017 - Financial

Paris, France, April 10, 2017 - Monthly information regarding the total number of voting rights and total number of shares of the Company
Read more

Cellnovo Appoints Erwan Martin as Chief Financial Officer

03/04/2017 - Corporate

Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces the appointment of Erwan Martin as Chief Financial Officer. Erwan replaces Thierry Moulin who has left the company to pursue other interests.
Read more

Cellnovo Announces Arrangement of an Equity Line to Support its Development

20/03/2017 - Financial

Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces today that it has arranged an equity line with Kepler Cheuvreux.
Read more

Cellnovo: 2016 Full-Year Sales

31/01/2017 - Financial

Cellnovo Group (“Cellnovo” CLNV:EN Paris, or “the Company”), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces today its revenue from sales and its cash position at December 31, 2016.
Read more

Information droits de vote et actions au 31 Décembre 2016 (In French Only)

10/01/2017 - Financial

Paris, France, le 10 janvier 2017 Cellnovo Group, Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Read more

Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (In French Only)

05/01/2017 - Financial

Paris, France, le 5 janvier 2017 Au titre du contrat de liquidité confié par la société CELLNOVO a CM-CIC Securities, en date du 31 décembre 2016, les moyens suivants figuraient au compte de liquidité :
Lire plus

Cellnovo and Diabeloop Update on Artificial Pancreas

05/01/2017 - Corporate

Paris, France, January 5, 2017 - Cellnovo Group (“Cellnovo” CLNV:EN Paris, or “the Company”), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system and Diabeloop, a privately held medical devices company, developing an Artificial Pancreas system, announce today that they have reached several milestones in their Artificial Pancreas programme.
Read more

Cellnovo update on progress towards full-scale manufacturing of insulin cartridges by Flex

16/11/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today provides an update on progress towards the buildup to full-scale manufacturing of its mobile, connected, all-in-one diabetes management system by Flex.
Read more

Cellnovo files for 510(k) approval with the FDA for its mobile, connected, all-in-one diabetes management system

16/11/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces today that it has filed for 510(k) approval with the US Food and Drug Administration (FDA) for marketing clearance of the Company's diabetes management system.
Read more

Cellnovo announces its 2017 financial calendar

07/11/2016 - Financial

Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today publishes its financial calendar for the year 2017.
Read more

Cellnovo annonce son éligibilité PEA-PME (In French only)

24/10/2016 - Corporate

Le groupe Cellnovo (“Cellnovo” CLNV: EN Paris), société de technologie médicale qui distribue la première micro-pompe connectée pour mieux gérer son diabète, annonce aujourd’hui son éligibilité au dispositif PEA-PME pour les 12 mois à venir, conformément au Décret n° 2014‐283 du 4 mars 2014 pris pour l'application de l'article 70 de la loi n° 2013‐1278 du 29 décembre 2013 de finances pour 2014, fixant les critères d'éligibilité des entreprises au PEA‐PME.
Read more

Cellnovo Reports Strong Sales Growth over the First 9 Months of 2016

20/10/2016 - Financial

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces its sales for the first nine months and third quarter ended September 30, 2016.
Over the first nine months of 2016, Cellnovo reported an increase in sales against the previous period, with revenues totaling €1.054 million.
Read more

Cellnovo Strengthens Board by appointing Rémi Soula as a Non-Executive Director

26/09/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, is pleased to announce the appointment of Rémi Soula as a Non-Executive Director.
Read more

Cellnovo raises circa EUR 5.4m in capital increase without preferential subscription rights

16/09/2016 - Financial

Cellnovo Group (“Cellnovo” CLNV: EN Paris or the “Company”), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces today that it has raised circa EUR 5.4 million from European and US institutional investors through a capital increase without preferential subscription rights.
Read more

Cellnovo announces its Half Year 2016 Results

13/09/2016 - Financial

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system today announced its financial results for the half-year ended 30 June, 2016.
Read more

Notice of Half Year Results

09/09/2016 - Financial

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, will announce its financial results for the half-year ended June 30, 2016 on Tuesday, September 13, 2016 at 7:00 AM CEST (French time).
Read more

First Batch of Cellnovo Insulin Cartridges Produced by Flex

06/09/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system today announces that delivery of the first batch of its Insulin cartridges produced by Flex (Flextronics), has been received. The delivery of this first batch of cartridges demonstrates that the automated manufacturing solution developed by Flex is complete.
Read more

Cellnovo Introduces Manual Blood Glucose Entry Feature for CGM Users

29/07/2016 - Corporate

Cellnovo Group, a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces a system upgrade which will allow patients using CGM (Continuous Glucose Monitoring) to input their glucose levels manually. This enhanced capability has been introduced to provide greater comfort, convenience and flexibility for the growing number of type 1 diabetes patients using CGM devices.
Read more

2016 First Half Sales

20/07/2016 - Financial

Cellnovo Group, a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces its sales for the first half and second quarter ended June 30, 2016.
Read more

New study highlights superior accuracy of Cellnovo Diabetes Management System compared to other leading patch pumps

22/06/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces the findings of a new in vitro study published in European Endocrinology. The study demonstrates that the Cellnovo Diabetes Management System is more accurate and consistent than the Insulet OmniPodÒ System (“OmniPod”), a tubeless insulin pump.
Read more

Cellnovo appoints John Brooks as Chairman of the Board of Directors

09/06/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, is pleased to announce the appointment of John Brooks as Chairman of the Board.
Read more

Assemblée Générale Mixte du 24 juin 2016. Modalités de mise à disposition des documents préparatoires (In French Only)

06/06/2016 - Financial

Le groupe Cellnovo (“Cellnovo” CLNV : EN Paris), société indépendante de technologie médicale qui distribue la première micro-pompe connectée pour mieux gérer son diabète, informe ses actionnaires et l’ensemble de la communauté financière que les documents relatifs à l’Assemblée Générale Mixte qui se tiendra le vendredi 24 juin 2016 à 10h, au siège de la société situé 13 rue de Londres, 75009 Paris, sont disponibles sur simple demande auprès de la société, ou peuvent être consultés sur le site Internet http://www.cellnovo.fr, rubrique Investisseurs / Documentation.
Read more

Mise à disposition du rapport financier annuel 2015 (In French Only)

02/05/2016 - Financial

Le groupe Cellnovo (“Cellnovo” CLNV : EN Paris), société indépendante de technologie médicale qui distribue la première micro-pompe connectée pour mieux gérer son diabète, annonce aujourd’hui avoir mis à la disposition du public et déposé auprès de l'Autorité des marchés financiers son rapport financier annuel au 31 décembre 2015.


Le rapport financier annuel 2015 peut être consulté sur le site internet de la société www.cellnovo.com rubrique Investisseurs / Documentation.

Read more

Cellnovo announces its Full Year 2015 Results and Q1 2016 Sales

27/04/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected all-in-one diabetes management system, today announced its full-year results for the financial year ended December 31, 2015, and its Q1 2016 sales.


Sophie Baratte, Chief Executive Officer of Cellnovo, commented:
2015 has been a pivotal year for Cellnovo. Since undertaking our initial public offering on Euronext last July, we have achieved a number of key commercial milestones for our unique all-in-one diabetes management system.

Read more

Cellnovo’s Diabetes Management System selected for inclusion in EUR 4 million diabetes self-management project

13/04/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces that it has been selected to participate in a project, funded by the European Commission’s Horizon 2020 programme, aimed at investigating new technologies to help improve the lives of people with Type 1 diabetes.


The project, named PEPPER (Patient Empowerment through Predictive Personalised decision support), has a budget of nearly EUR 4 million and brings together leading UK and European universities and companies to research and develop technology that will help to improve the self-management of people with Type 1 diabetes.

Read more

Cellnovo appoints Sophie Baratte as Interim Chairman of the Board

11/04/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected all-in-one diabetes management system, today announced that Eric Beard has stepped down as Chairman of the Board for personal reasons, effective immediately. Sophie Baratte, CEO of Cellnovo, will assume the role of Interim Chairman whilst the Board searches for a permanent successor.
Read more

Cellnovo and Roche Sign Commercial Blood Glucose Monitor Agreement

15/03/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected all-in-one diabetes management system, today announces the signing of a commercial agreement to integrate Roche Diabetes Care’s market leading Accu-Chek® Aviva and Accu-Chek® Performa blood glucose monitoring (BGM) platforms into the Cellnovo diabetes management system.


Cellnovo will build in the Accu-Chek® Aviva or Accu-Chek® Performa monitoring platforms into its newly developed, next generation e-connected handset which was CE-marked earlier this month. The Roche BGM platform will replace the LifeScan OneTouch® Vita BGM currently used. The redesign of the handset will also enable an increase in productivity at Cellnovo’s manufacturing site, due to a reduced assembly time.

Read more

Cellnovo reaches first insulin cartridge industrialisation milestone

25/02/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces that its first industrialisation milestone with Flex has been reached. This is consistent with the manufacturing transfer plan, announced last year, that will bring an increase in the production capacity of Cellnovo’s diabetes management system in the second part of 2016.

Cellnovo began transferring the manufacturing of its disposable insulin cartridges to Flex in Q3 2015 and is benefitting from Flex’s industry-leading experience in automation and manufacturing of medical devices.
Read more

Cellnovo appoints Thierry Moulin as Chief Financial Officer

22/02/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces the appointment of Thierry Moulin as the Company’s Chief Financial Officer with immediate effect.


Thierry Moulin joins Cellnovo from the multinational biopharmaceutical company Cellectis, where he served as Chief Financial Officer since 2014, overseeing a $228 million fundraise via a public listing on the Nasdaq in March 2015. During his time at Cellectis he also contributed to an extensive programme of restructuring through mergers, divestitures and reallocation of resources.

Read more

Cellnovo to Market its Diabetes Management System in Italy

11/02/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first connected all-in-one diabetes management system, today announces it has completed the full registration process required by the Italian Ministry of Health for medical devices and is now able to import and distribute the Cellnovo diabetes management system in Italy.
Read more

Cellnovo Partners with US Company TypeZero on Artificial Pancreas Programme

05/02/2016 - Corporate

Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announced today that it is partnering with the technology company, TypeZero, to utilise Cellnovo’s e-connected insulin patch pump alongside its inControl AP software in an artificial pancreas (AP) programme. This joint system will be in consideration for use in the International Diabetes Closed Loop Trial (IDCL), which is funded by the National Institute of Health (NIH), a part of the U.S. Department of Health Services.


The artificial pancreas is designed to automatically monitor and regulate blood-sugar levels in people with Type 1 diabetes through the delivery of insulin.

Read more

Cellnovo: 2015 Full Year sales

20/01/2016 - Financial

Cellnovo Group today announces its revenue from sales and cash position at December 31, 2015.
Read more

Half-Yearly report on the liquidity contract With CM-CIC Securities

14/01/2016 - Financial

Pursuant to the liquidity contract entrusted by CELLNOVO to CM-CIC Securities, as of December 31, 2015, the following assets appeared on the liquidity account:
  • 8,036 shares CELLNOVO
  • Cash balance of the liquidity account: €178,470.52
Read more

Monthly information regarding the total number of voting rights and total number of shares of the Company

14/01/2016 - Financial

Article L233-8-II of the Commercial code. Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
Read more

Cellnovo admitted to the SRD long-seulement Long-only Deferred Settlement Service

10/12/2015 - Financial

Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces that its shares will be admitted to the Euronext Paris SRD (Service de Règlement Différé, i.e. Deferred Settlement Service) from 29 December 2015, on the “Long-seulement” (Long-only) segment.
Read more

Cellnovo's Diabetes Management System featured in NHS alliance Programme 'Communities Of Care'

09/12/2015 - Corporate

Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces that its diabetes system has been featured as an exemplar in the NHS Alliance’s news-style programme entitled ‘Communities of Care’, produced in partnership with ITN Productions. The programme was premiered at the NHS Alliance’s event hosted in ITN Productions’ studio last night.
Read more

Appointment of Javaid Masoud as Chief Technology Officer

07/12/2015 - Corporate

Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces that Javaid Masoud has been appointed as Chief Technology Officer effective immediately.


Mr. Masoud has a proven track record of bringing new medical technologies from concept to product release with a system perspective. Working in the US and Europe, he is recognized for his consistent results and effective leadership in technology and product development by leading multi-functional international teams.

Read more

Cellnovo to Present at the 2015 Canaccord Genuity Medical Technology & Diagnostics Forum

19/11/2015 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first connected all-in-one diabetes management system, today announces that Sophie Baratte, Chief Executive Officer of Cellnovo, is scheduled to present at the Canaccord Genuity Medical Technology & Diagnostics Forum today at 1:00 pm EDT. The conference will be held at the Westin Grand Central in New York, NY.


A live webcast of Cellnovo’s presentation can be accessed via the following link: http://wsw.com/webcast/canaccord20/clnv.pa. An archived audio of the discussion will also be available on Cellnovo’s website for 90 days.

Read more

Cellnovo presents its unique mobile diabetes management system at Nordic Mobile Health Technology Congress

16/11/2015 - Corporate

Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first connected all-in-one diabetes management system, today announced that Dr. Julian Shapley, Chief Scientific Officer and inventor of Cellnovo’s unique pump technology, presented Cellnovo’s mobile diabetes management system at the Nordic Mobile Health Technology Congress in Stockholm on November 11th and 12th.
Read more

Cellnovo records strong sales growth over the first 9 months of 2015

22/10/2015 - Financial

Cellnovo Group (“Cellnovo”), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, today announced sales for the third-quarter and nine-months ended September 30th, 2015.


Sophie Baratte, CEO of Cellnovo, comments: “We are very pleased with our sales growth over the first 9 months of 2015, which validates our business strategy. Since our recent IPO, we continue our commercial development efforts in France and the UK, confirming the strong interest of both medical community and patients for our all-in-one Diabetes Management System. This growing adoption of our patch pumps makes us confident in our top-line growth in the next quarters.”

Read more

Cellnovo expands its organisation

09/10/2015 - Corporate

Cellnovo Group (“Cellnovo”), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, today announced that Eric Beard will transition from CEO and Executive Chairman of the board of directors to Non-Executive Chairman, effective October 1st. Mr. Beard has served as Chairman on the company’s board of directors since 2011 and was appointed Executive Chairman in September 2012.
Read more

Cellnovo expands partnership with Flex as it begins high-volume manufacturing of its connected all-in-one diabetes management system

29/09/2015 - Corporate

Cellnovo Group (“Cellnovo”), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, today announced the launch of its extended high-volume manufacturing partnership with Flex (formerly Flextronics), for the production and assembly of Cellnovo disposable insulin cartridges. As a global sketch-to-scale™ solutions company that designs and builds intelligent products for a connected world, Flex is the ideal partner to support Cellnovo take the manufacturing of its product to the next level.
Read more

Financial Calendar

22/09/2015 - Financial

Cellnovo Group (“Cellnovo”), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, announced today that it has been selected to incorporate three indexes of the Euronext CAC family: CAC® Small, CAC® Mid & Small and CAC® All-Tradable. The company also publishes its financial calendar for the end of 2015 and the year 2016.

Cellnovo member of the Euronext indexes CAC® Small, CAC® Mid & Small and CAC® All-Tradable

The inclusion of Cellnovo shares in these indexes is the result of a share liquidity analysis made by Euronext on the basis of two criteria: amount of capital traded and free float market capitalization. The scope of the liquidity criteria highlights the marked interest from investors for Cellnovo, despite the recent listing of the company. These indexes are used as references by a number of mutual and SICAV open-end investment funds.

Read more

Full exercise of the overallotment option

16/07/2015 - Financial

Cellnovo Group (« Cellnovo »), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, announces that Société Générale, acting in the name and on behalf of the Managers, has fully exercised the overallotment option of the 80,000 additional new shares at the offer price of €10.63 per share. Consequently, the total number of Cellnovo shares offered as part of the IPO reaches 3,049,557 new shares.


Furthermore, in accordance with Article 631-10 of the Autorité des marchés financiers ("AMF") General Rules, Société Générale, acting as stabilizing agent, has conducted stabilizing operations on the Cellnovo shares (FR0012633360 – CLNV) that started on July 10, 2015 and ended on the same day, at a price of €10.63 per share.

Read more

Success of Cellnovo's IPO with €31.6 million raised on Euronext in Paris

09/07/2015 - Corporate

Cellnovo Group (« Cellnovo »), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, today announces the success of its Initial Public Offering in compartment C of the Euronext regulated market in Paris ("Euronext Paris"), raising €31.56 million through a capital increase.


The Open Price Offering and the Global Placement price has been set at €10.63 per share. The total number of shares issued will be 2,969,557, resulting in a capital increase of €31.56 million. Based on a total of 10,683,873 shares to be admitted to the market and a price of €10.63 per share, Cellnovo’s market capitalization will be €113.6 million at the end of the operation. Cellnovo has granted Société Générale acting in the name and on behalf of the banking syndicate an overallotment option, exercisable from today until August 7, 2015 included, on a maximum of 80,000 new shares or approximately €0.85 million.

Read more

Cellnovo launches its IPO on the Euronext regulated market in Paris

29/06/2015 - Corporate

Cellnovo Group (« Cellnovo »), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, today announces the launch of its initial public offering on the regulated market of Euronext Paris ("Euronext Paris").


Following the registration of its document de base under number I.15-008 on February 27, 2015, the Autorité des marchés financiers (AMF) granted visa n°15-313 on June 26th, 2015, for the prospectus relative to the listing of Cellnovo.

Read more

Cellnovo Starts the Expansion of its Distribution Network

19/06/2015 - Corporate

Cellnovo Group (“Cellnovo”), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, today announces that it has started to expand its distribution network in a number of countries, and has now planned to launch its IPO project in the upcoming weeks.


Cellnovo already launched the marketing of its insulin patch pump system in the United Kingdom and France in 2014 via a direct sales force. Its commercialization is now being extended to other countries via a network of key distributors.

Read more

Cellnovo Joins the Diabeloop© Artificial Pancreas Development Programme

17/06/2015 - Corporate

Cellnovo Group (“Cellnovo”), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, announced today that it had joined the Diabeloop© Artificial Pancreas Programme and had released a new version of its insulin pump software.


Cellnovo is announcing that it is joining the Diabeloop© Artificial Pancreas program by supplying its unique patch pump and mobile diabetes management technologies. Diabeloop© is a research association between the CERIDT, a general interest leading diabetes research institution and service provider in France and the CEA-LETI, the French government’s main research and development institution. Ten leading French university hospitals are participating in this project. The Cellnovo R&D team will be joining the Diabeloop© research consortium by further developing its pump and handset software to allow the development of an artificial pancreas system. The overall Diabeloop© project is currently the subject of a special financing application with the French government in the form of an FUI (Fonds Unique Interministériel).

Read more

PR registration of document de base

03/02/2015 - Financial

Cellnovo Group (« Cellnovo »), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, announces the registration of its document de base with the Autorité des Marchés Financiers (AMF), under number I.15-008 on February 27, 2015.


The registration of the document de base is the first step towards the Initial Public Offering of Cellnovo’s shares on the regulated market of Euronext in Paris, subject to market conditions and regulatory pre-requisites, in particular the AMF’s visa on the prospectus to be prepared in respect of the proposed transaction.

Read more
  • 1
New Call-to-action